Cargando…

Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept

BACKGROUND: To compare a treat-to-target (T2T) approach and routine care (RC) in adults with active to severely active rheumatoid arthritis (RA) initiating subcutaneous abatacept. METHODS: A 12-month cluster-randomized trial in active RA patients treated with abatacept was conducted. Physicians were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bessette, Louis, Haraoui, Boulos, Rampakakis, Emmanouil, Dembowy, Joanna, Trépanier, Marc-Olivier, Pope, Janet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537125/ https://www.ncbi.nlm.nih.gov/pubmed/37759330 http://dx.doi.org/10.1186/s13075-023-03151-2

Ejemplares similares

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
por: Choquette, Denis, et al.
Publicado: (2019)

Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population
por: Haraoui, Boulos, et al.
Publicado: (2015)

Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report
por: Qi, Jia-Ping, et al.
Publicado: (2023)

Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept
por: Ospina, Fabio E., et al.
Publicado: (2014)

Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients
por: Imberti, Luisa, et al.
Publicado: (2015)

Etanercept in the treatment of rheumatoid arthritis
por: Haraoui, Boulos, et al.
Publicado: (2007)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

Abatacept in difficult-to-treat juvenile idiopathic arthritis
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2008)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Analysis of Mitogen-Activated Protein Kinases in Bone and Cartilage of Patients with Rheumatoid Arthritis Treated with Abatacept
por: Kanbe, Katsuaki, et al.
Publicado: (2016)

Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
por: Choy, Ernest, et al.
Publicado: (2021)

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
por: Westhovens, Rene, et al.
Publicado: (2015)

Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry
por: Rahman, Proton, et al.
Publicado: (2017)

Fatal Chronic Active Epstein-Barr Virus Infection in a Rheumatoid Arthritis Patient Treated with Abatacept
por: Kawabe, Akio, et al.
Publicado: (2018)

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
por: Roubille, Camille, et al.
Publicado: (2015)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis
por: Köller, Marcus D.
Publicado: (2007)

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
por: Lutt, Joseph R
Publicado: (2009)

The Use of Abatacept for the Treatment of Felty Syndrome in Rheumatoid Arthritis
por: Chin, Rishika V, et al.
Publicado: (2023)

Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
por: Fleischmann, Roy, et al.
Publicado: (2022)

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
por: Westhovens, R, et al.
Publicado: (2009)

Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis
por: Keystone, Edward C., et al.
Publicado: (2016)

Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials
por: Michaud, Kaleb, et al.
Publicado: (2023)

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
por: Caporali, Roberto, et al.
Publicado: (2022)

The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
por: Pope, Janet E, et al.
Publicado: (2014)

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
por: Pope, Janet E., et al.
Publicado: (2019)

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
por: Salmon, Jean-Hugues, et al.
Publicado: (2020)

Subcutaneous abatacept in rheumatoid arthritis: A real-life experience
por: Sarmiento-Monroy, Juan Camilo, et al.
Publicado: (2019)

Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
por: Yokoyama-Kokuryo, Waka, et al.
Publicado: (2020)

Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy
por: Kunishita, Yosuke, et al.
Publicado: (2023)

Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study
por: Bessette, Louis, et al.
Publicado: (2019)

Treating rheumatoid arthritis to target: recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2010)

Change of ARASHI scores for large joints in rheumatoid arthritis patients treated with abatacept for three years: A clinical observational study
por: MOCHIZUKI, Takeshi, et al.
Publicado: (2020)

Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs
por: Patel, Vardhaman, et al.
Publicado: (2022)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis
por: Derambure, Céline, et al.
Publicado: (2020)

Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate
por: Benucci, Maurizio, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5rfvq4s1663sk9os9ahnsmlkot